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Background: Increasing bacterial resistance to antibiotics is one of the most serious problems in current medicine.
An important factor contributing to the growing prevalence of multiresistant bacteria is application of antibiotics.
This study aimed at analyzing the development of resistance of Enterobacteriaceae to selected beta-lactam,
fluoroquinolone and aminoglycoside antibiotics in the University Hospital Olomouc and assessing the effect of
selection pressure of these antibiotics.
Methods: For the period between 1 January 2000 and 31 December 2011, resistance of Klebsiella pneumoniae,
Escherichia coli, Enterobacter cloacae and Proteus mirabilis to third- and fourth-generation cephalosporins, meropenem,
piperacillin/tazobactam, fluoroquinolones and aminoglycosides was retrospectively studied. For the assessment
of selection pressure of antibiotics, a parameter of defined daily dose in absolute annual consumption (DDDatb)
based on the ATC/DDD classification and in relative annual consumption (RDDDatb) as the number of defined
daily doses per 100 bed-days was used. The relationship between frequency of strains resistant to a particular
antibiotic and antibiotic consumption was assessed by linear regression analysis using Spearman’s correlation.
The level of statistical significance was set at p < 0.05.
Results: A total of 113,027 isolates from the Enterobacteriaceae family were analyzed. There was a significant
effect of selection pressure of the primary antibiotic in the following cases: piperacillin/tazobactam in Klebsiella
pneumoniae, gentamicin in Klebsiella pneumoniae and Escherichia coli and amikacin in Escherichia coli and
Enterobacter cloacae. Also, there was significant correlation between resistance to ceftazidime and consumption
of piperacillin/tazobactam in Klebsiella pneumoniae and Escherichia coli. No relationship was found between
consumption of third- and fourth-generation cephalosporins and resistance to ceftazidime or between fluoroquinolone
consumption and resistance to ciprofloxacin.
Conclusion: The study showed the effects of both direct and indirect selection pressure on increasing resistance to
gentamicin, amikacin, piperacillin/tazobactam and ceftazidime. Given the fact that no correlation was found between
resistance to fluoroquinolones and consumption of either primary or secondary antibiotics, we assume that the increasing
resistance to fluoroquinolones is probably due to circulation of resistance genes in the bacterial population and that this
resistance was not affected by reduced use of these antibiotics.
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Gram-negative bacteria are currently the most frequent
cause of nosocomial infections. Apart from Pseudomonas
aeruginosa, these are mainly members of the Enterobacte-
riaceae family, most frequently Klebsiella pneumoniae,
Escherichia coli, Enterobacter spp., Proteus mirabilis etc.
In the University Hospital Olomouc (UHO; 1148 beds;
50,000 hospitalized patients per year), Enterobacteriacae
are the most frequent pathogens causing nosocomial
infections. For instance, they are responsible for 59%
of nosocomial pneumonia cases [1]. Infections due to
these bacteria are mostly treated with beta-lactam anti-
biotics, often conveniently combined with aminoglyco-
sides and, in some cases, with fluoroquinolones. A
significant problem in intensive care units is constantly
increasing resistance to these antibiotics. It is known
from earlier studies that bacterial resistance frequently
results in inadequate antibiotic therapy, thus increas-
ing morbidity and mortality rates and prolonging treat-
ment and increasing treatment costs [2-4].
Resistance of Gram-negative bacteria to broad-spectrum
penicillins and cephalosporins is currently so high that
these important drug groups are very likely to lose
their effectiveness. A 2006 study by Kolář et al. docu-
mented 39% prevalence of ESBL-positive strains of
Klebsiella pneumoniae in intensive care units in the
Czech Republic [5]. In 2011, the resistance of this spe-
cies to third-generation cephalosporins in the Depart-
ment of Anesthesiology and Intensive Care Medicine,
UHO, reached 60% (unpublished data). Resistance to
piperacillin/tazobactam was 63% and to fluoroquino-
lones even 67% (unpublished data). It is therefore ne-
cessary to analyze the development and the causes of
resistance and to adjust administration of antibiotics to
that trend.
The increase in bacterial resistance is contributed to
by selection pressure of antibiotics, the clonal spread
of multiresistant bacterial strains and recombination
processes such as conjugation. Because of a different
approach to preventing the spread of resistance it is
important to differentiate whether the higher preva-
lence of multiresistant bacteria is caused by increased
prescription of antibiotics or by clonal, horizontal
spread. Selection pressure may be reduced by rational
antibiotic policy and clonal spread of resistant strains
may be reduced by adhering to hygiene and epidemi-
ology principles. On the other hand, the transfer of
mobile elements between bacterial cells cannot be sig-
nificantly influenced in clinical practice.
This study aimed at analyzing the development of
Enterobacteriaceae resistance to selected beta-lactam,
fluoroquinolone and aminoglycoside antibiotics and
particularly at assessing the effect of selection pressure
of these antibiotics.Methods
Group of bacterial strains
For the period between 1 January 2000 and 31 December
2011, a retrospective study was performed to assess the
resistance of selected Enterobacteriaceae spp. (Klebsiella
pneumoniae, Escherichia coli, Enterobacter cloacae and
Proteus mirabilis) to selected beta-lactam, fluoroquinolone
and aminoglycoside antibiotics. Bacterial strains were iso-
lated from clinical samples (blood, urine, other body fluids
and exudates, lower airway samples, needle biopsy samples,
intravascular catheters, dialysate etc.) collected from UHO
inpatients. Strains were selected from each patient in the
following way: only one strain of a particular species was in-
cluded which was isolated from a relevant sample as the
first one over a time interval of 90 days. Identification was
performed using standard microbiology procedures using
the ENTEROtest 16 (Erba Lachema s.r.o.) and, in selected
cases, the Phoenix automated system (Becton Dickinson)
and MALDI-TOF (Biotyper Microflex, Bruker Daltonics).
The isolates were collected as part of standard patient
care and no ethical approval was needed.
Determining susceptibility to antimicrobial agents
Susceptibility to antibiotics was determined by the standard
microdilution method according to the EUCAST criteria
[6]. Reference strains Escherichia coli ATCC 25922,
Escherichia coli ATCC 35218 and Pseudomonas aerugi-
nosa ATCC 27853 were used for protocol quality con-
trol. Beta-lactamase phenotypes were determined by
relevant phenotype tests and, if needed, the results
were confirmed by detection of genes encoding the en-
zymes [7,8].
Antibiotic consumption
Administration of antimicrobial agents and their selection
pressure were assessed based on antibiotic consumption in
the UHO between 2000 and 2011. The consumption data
were obtained from the database of the hospital’s De-
partment of Pharmacology. The utilization of individ-
ual antibiotics was expressed as absolute (total) annual
consumption (DDDatb) in defined daily doses (DDD),
based on the WHO ATC/DDD classification [9]. The
relative annual consumption of antibiotics (RDDDatb)
was determined as the number of defined daily doses
per 100 bed-days (DBD) [10].
In order to assess selection pressure, association be-
tween resistance of the above enterobacteria to ceftazi-
dime, piperacillin/tazobactam, ciprofloxacin, gentamicin
and amikacin and consumption of relevant antibiotic
groups (third- and fourth-generation cephalosporins,
fluoroquinolones and aminoglycosides) and piperacillin/
tazobactam was tested. Additionally, the relationship
between the trends in resistance to the antibiotics and
consumption of secondary antibiotics, i.e. drugs from
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the same group, was assessed. The relationship between
frequency of strains resistant to a particular antibiotic
and antibiotic consumption was assessed by linear re-
gression analysis using Spearman’s correlation. The level
of statistical significance was set at p < 0.05.
Results
Over the study period, a total of 113,027 isolates from
the Enterobacteriaceae family (34,417 isolates of Klebsi-
ella pneumoniae, 60,262 isolates of Escherichia coli,
3,624 isolates of Enterobacter cloacae and 14,724 isolates
of Proteus mirabilis) were analyzed. The development of
bacterial resistance to selected antibiotics is documented
in Table 1. Resistance to third- and fourth-generation
cephalosporins and piperacillin/tazobactam increased in
all the studied species, with the exception of Proteus
mirabilis. The increasing trend in resistance of Klebsiella
pneumoniae appeared to be very serious. For instance,
the resistance to ceftazidime increased from 5% in 2000
to 40% in 2011. In piperacillin/tazobactam, the increase
was even greater; from 12% to 42%.
Over the same period, resistance to ciprofloxacin in-
creased in all species, the highest being in Klebsiella
pneumoniae (from 5% in 2000 to 44% in 2011) and
Proteus mirabilis (from 7% in 2000 to 36% in 2011).
Resistance of Klebsiella pneumoniae and Escherichia
coli to gentamicin gradually increased over the entire
period (from 12% in 2000 to 37% in 2011 and from 3%
in 2000 to 7% in 2011, respectively). In Enterobacter clo-
acae, the resistance initially decreased. However, from
2006, it increased, this being the same at the end as at
the beginning of the study period, i.e. 15%. In Proteus
mirabilis, the resistance even dropped from 48% in 2000
to 20% in 2011.
High susceptibility to meropenem and amikacin, i.e.
88-100%, remained unchanged in all the species throughout
the entire period.
The relative annual consumption of the total amount
of all antibiotics in the UHO rose by 21% between the
years 2000 and 2011. The absolute and relative con-
sumption rates of particular antibiotic groups are shown
in Table 2. Correlation power, including statistical sig-
nificance, is shown in Table 3. Statistically significant
correlations were found between piperacillin/tazobactam
consumption and resistance of Klebsiella pneumoniae
(r = 0.85; p = 0.01) to this antibiotic, and between pipera-
cillin/tazobactam consumption and resistance of Klebsiella
pneumoniae (r = 0.84; p = 0.01) and Escherichia coli
(r = 0.89; p = 0.01) to ceftazidime. There were also signifi-
cant correlations between aminoglycoside consumption
and resistance to gentamicin in Escherichia coli (r = 0.69;
p = 0.02) and Klebsiella pneumoniae (r = 0.64; p = 0.03)
and to amikacin in Escherichia coli (r = 0.74; p = 0.01) andEnterobacter cloacae (r = 0.63; p = 0.04). Non-significant
positive correlations were shown in resistance of Klebsiella
pneumoniae and Escherichia coli to the other antibiotics.
Similarly, Proteus mirabilis was also found to have only
statistically non-significant correlations.
The correlations between antibiotic consumption and
development of resistance are shown in Figures 1, 2,
3 and 4.
Discussion and conclusions
Our work focused on the changing role of antibiotic se-
lection pressure in the spread of bacterial resistance in
Enterobacteriaceae in the 12-year period in the UHO.
Although the total consumption of antibiotics increased
during the study period, the use of antibiotics with
the highest selection pressure potential such as third-
generation cephalosporins and fluoroquinolones de-
creased. The growing use of antibiotics can be justified
by a rising number of bacterial infections in the univer-
sity hospital, i.e. a facility treating the most seriously ill
patients at a higher risk of developing bacterial infec-
tions. On the other hand, lower consumption of third-
generation cephalosporins and fluoroquinolones results
from strict antibiotic policy implemented by the hospital’s
antibiotic centre.
The presented results are indicative of a direct relation-
ship between antibiotic consumption and resistance in pi-
peracillin/tazobactam and aminoglycosides. Also suggested
is indirect influence of selection pressure of secondary anti-
biotics in the case of piperacillin/tazobactam consumption
and resistance to ceftazidime. Finally, in fluoroquinolones,
no influence of selection pressure on the increasing trend
of resistance was observed.
In the last two decades, several studies have been car-
ried out on the relationship between consumption of
antimicrobial agents and development of bacterial resist-
ance, suggesting a positive correlation. Kolář et al. inves-
tigated the development of resistance in Gram-negative
bacteria in 1994 – 1998 and assessed its association with
consumption of various groups of antibiotics. They re-
ported a statistically significant correlation between
development of bacterial resistance and consumption
of cephalosporins and fluoroquinolones [11]. A study
by Urbánek et al. performed between 1997 and 2005
confirmed a positive correlation between the prevalence of
ESBL-positive isolates of Klebsiella pneumoniae and con-
sumption of third-generation cephalosporins [12]. These
and other cases may document the widely accepted hypoth-
esis of selection pressure and its impact on an increasing
resistance to antimicrobial agents [13-15]. Our study
showed a direct effect of selection pressure for increasing
resistance only to gentamicin, amikacin and piperacillin/
tazobactam. In a clear contrast to the aforementioned study
of Kolář et al., resistance of Enterobacteriaceae to third-
Table 1 Development of Enterobacteriaceae resistance to selected antibiotics in the UHO in 2000–2011
(in percentages)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
CPR KLPN 18 22 19 14 14 16 11 20 42 39 41 41
ESCO 4 4 2 2 2 3 4 10 11 12 12 11
ENCL 15 18 22 21 24 15 15 22 30 23 35 32
PRMI 4 6 2 2 2 2 2 2 2 2 2 2
CTX KLPN 5 7 6 5 11 12 8 14 38 37 39 40
ESCO 1 1 1 1 1 1 2 7 9 11 11 10
ENCL 10 18 23 23 24 18 17 24 29 23 35 32
PRMI 1 1 1 1 0 1 1 0 0 1 1 1
CTZ KLPN 5 7 6 7 12 17 24 24 42 37 40 40
ESCO 1 1 1 1 2 2 3 8 10 11 11 10
ENCL 6 18 23 26 24 19 17 26 30 23 35 32
PRMI 2 1 1 0 1 0 0 1 0 1 1 1
CPM KLPN NT 5 4 3 4 3 2 11 34 30 36 36
ESCO NT 1 0 0 1 0 1 6 8 10 10 9
ENCL NT 8 5 1 4 1 2 2 6 8 5 13
PRMI NT 1 1 0 0 1 0 0 0 1 0 0
MER KLPN 0 0 0 0 1 1 0 0 0 0 0 1
ESCO 0 0 0 0 0 0 1 1 0 0 0 0
ENCL 0 3 0 2 0 2 1 1 1 1 0 0
PRMI 0 0 1 0 0 0 1 0 0 0 0 0
PPT KLPN 12 19 13 10 11 12 23 31 41 40 43 42
ESCO 1 2 2 2 2 2 3 9 9 12 12 11
ENCL 7 13 27 17 16 10 9 20 29 23 35 33
PRMI 2 1 1 1 1 1 1 1 1 1 1 1
OFL KLPN 6 8 15 10 10 11 29 28 30 36 38 41
ESCO 3 5 5 8 10 13 15 19 22 21 23 21
ENCL 3 6 5 2 3 4 3 6 7 6 15 10
PRMI 11 14 14 17 19 17 22 29 33 34 35 33
CIP KLPN 5 10 17 13 10 13 31 30 46 40 42 44
ESCO 4 6 6 10 11 14 17 22 26 23 26 23
ENCL 2 6 5 1 4 4 2 7 9 6 17 11
PRMI 7 16 17 20 18 16 23 29 36 37 39 36
GEN KLPN 12 15 17 17 19 17 17 18 35 32 37 37
ESCO 3 4 4 4 5 7 6 8 9 8 8 7
ENCL 15 5 0 4 2 4 1 5 8 4 6 15
PRMI 48 39 30 23 22 21 18 17 19 21 20 20
AMI KLPN 2 6 7 5 3 8 4 5 12 8 12 8
ESCO 1 1 1 0 0 0 1 2 2 2 5 4
ENCL 2 2 1 1 0 0 1 2 2 2 2 2
PRMI 2 5 4 2 2 1 1 2 5 2 3 1
Legend: CPR - cefoperazone, CTX - cefotaxime, CTZ - ceftazidime, CPM - cefepime, MER - meropenem, PPT - piperacillin/tazobactam, OFL - ofloxacin, CIP - ciprofloxacin,
GEN - gentamicin, AMI - amikacin, KLPN - Klebsiella pneumoniae, ESCO - Escherichia coli, ENCL - Enterobacter cloacae, PRMI - Proteus mirabilis, NT - not tested.
Sedláková et al. BMC Research Notes 2014, 7:454 Page 4 of 10
http://www.biomedcentral.com/1756-0500/7/454
Table 2 Absolute annual consumption of selected antibiotics (DDDatb) in DDDs and relative annual consumption of antibiotics (RDDDatb) in DDD per 100
bed-days (DBD) at the UHO over the study period
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Third- and fourth-generation cephalosporins DDDatb 3,725.5 4,925 4,742.4 6,065.9 6,447.3 5,504.6 6,019.45 5,981 5,886.13 4,417.88 4,640 4,148.25
RDDDatb 1.01 1.34 1.32 1.57 1.66 1.52 1.74 1.69 1.65 1.27 1.35 1.31
Piperacillin/tazobactam DDDatb 1,715.20 1,703.60 968.40 1,563.60 1,744.50 2,461.60 1,692.80 2,643.50 2,590.77 3,873.13 4,049.81 3,778.91
RDDDatb 0.46 0.46 0.27 0.41 0.45 0.68 0.49 0.75 0.73 1.11 1.18 1.20
Fluoroquinolones DDDatb 13,056.50 14,515.40 14,092.80 15,887.60 13,411.90 16,246.20 14,941.70 15,344.60 16,614.40 13,228.50 11,267.10 10,743.10
RDDDatb 3.54 3.96 3.92 4.12 3.46 4.47 4.31 4.33 4.65 3.81 3.28 3.40
Aminoglycosides DDDatb 8,455 7,928.9 7,468.4 8,879.3 8,121.7 8,183.6 8,338.1 9,915.50 9,555.92 10,625.54 8,418.23 10,437.27
RDDDatb 2.29 2.16 2.08 2.3 2.1 2.25 2.4 2.8 2.68 3.06 2.45 3.31
Total consumption of antibiotics DDDatb 171,316 172,463 142,822 161,919 146,848 164,857 167,993 184,238 186,943 187,945 192,398 177,030



















Table 3 Results of Spearman’s correlation showing the relationship between frequency of strains resistant to a
particular antibiotic and consumption of antibiotics potentially showing selection pressure
Correlation 2000-2011 Statistical values
Consumption of antibiotics Bacterial resistance R p
































R – Spearman’s rank correlation coefficient, p - statistical significance.
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increased despite the lower use of these antibiotics. This
implied correlation between the consumption of these two
antibiotic groups and the bacterial resistance was not
confirmed. Moreover, susceptibility of Proteus mirabilis to
piperacillin/tazobactam and gentamicin was found to stag-
nate despite their increased use. It can be supposed that at
present, bacterial resistance is not as directly dependent on
the consumption of a particular antibiotic as shown by earl-
ier studies.Other, later studies showed an indirect relationship be-
tween consumption of a particular antibiotic and bacter-
ial resistance to other antibiotics. A two-year study by
Haller, performed in 2003 – 2004, showed a significant
correlation between the use of second-generation cephalo-
sporins and increasing prevalence of strains of Enterobacter
spp. resistant to third-generation cephalosporins [16]. How-
ever, in the case of a direct relationship, i.e. the relationship
between resistance to third-generation cephalosporins and/














































Figure 1 Development of resistance of selected Enterobacteriaceae to ceftazidime with respect to consumption of third- and
fourth-generation cephalosporins in the UHO in 2000 – 2011. Legend: RDDD CEF – relative annual consumption of third- and
fourth-generation cephalosporins in the UHO in 2000 – 2011, KLPN - Klebsiella pneumoniae, ESCO - Escherichia coli, ENCL - Enterobacter
cloacae, PRMI - Proteus mirabilis.
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tigated the association between antibiotic consumption and
resistance in Enterobacteriaceae, finding that increasing or
decreasing trends in resistance did not correlate with con-
sumption of the primary antibiotic in any of the studied
cases. However, dependence on consumption of secondary
antibiotics was confirmed [17]. There were significant posi-
tive correlations between ciprofloxacin-resistant Escherichia
coli and ceftriaxone consumption and between cefepime-
resistant Enterobacter cloacae and piperacillin/tazobactam
consumption. Bosso’s findings are consistent with the re-





















Figure 2 Development of resistance of selected Enterobacteriaceae to
in the UHO in 2000 – 2011. Legend: RDDD FQ – relative annual consumpnot be dependent on the use of a primary antibiotic; and
decreased consumption of the primary antibiotics may not
necessarily result in decreased resistance. Also Meyer et al.,
in their five-year interventional study, reported that
after standard therapy of abdominal infections with
third-generation cephalosporins had been changed to
piperacillin/tazobactam combination, the resistance to
third-generation cephalosporins did not decrease as it had
been expected [18]. Meyer admitted the hypothesis that pi-
peracillin/tazobactam combination may, through its selec-
tion pressure, increase the prevalence of Enterobacteriaceae



























ciprofloxacin with respect to consumption of fluoroquinolones














































Figure 3 Development of resistance of selected Enterobacteriaceae to piperacillin/tazobactam with respect to consumption of this
antibiotic in the UHO in 2000 – 2011. Legend: RDDD PPT – relative annual consumption of piperacillin/tazobactam in the UHO in 2000 – 2011.
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tazobactam correlated with the increasing trend of broad-
spectrum cephalosporins resistance.
There are studies showing an interesting role of fluor-
oquinolones in antibiotic resistance. Similar to our study,
a study by Spanish authors on the prevalence of Entero-
bacteriaceae resistant to broad-spectrum cephalosporins
and fluoroquinolones in 1999 – 2010 and consumption
of antibiotics in Spanish hospitals reported no correlation
between the consumption of broad-spectrum cephalospo-
rins and their resistance trends. However, the effect of
fluoroquinolone administration on increasing resistance in
both groups of antimicrobial agents was observed [19]. Our

















Figure 4 Development of resistance of selected Enterobacteriaceae to
the UHO in 2000 – 2011. Legend: RDDD AMG – relative annual consumpresistance in these two antibiotic groups. The resistance to
ciprofloxacin rises progressively although the consumption
of fluoroquinolones and broad-spectrum cephalosporins
decreased years ago. Our results imply that selection
pressure might be not an explanation for the increasing
prevalence of fluoroquinolone-resistant Enterobacteriaceae.
From these facts, it may be assumed that the relation-
ship between resistance and antibiotic administration is
probably determined by additional factors and it cannot
be influenced by a mere decrease in consumption. There
are two other mechanisms of bacterial resistance spread
besides the selective pressure: horizontal clonal spread
of the identical multiresistant isolates and recombination


























gentamicin with respect to consumption of aminoglycosides in
tion of aminoglycosides in the UHO in 2000 – 2011.
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tion of resistant strains, as documented by some pub-
lished papers [1,20,21]. After excluding the two above
mechanisms, i.e. the selection pressure and the clonal
spread of identical isolates, the increasing resistance
rates in Enterobacteriaceae are thought to be caused by
recombination mechanisms.
It is likely that the hypothesis of direct relationship be-
tween the total amount of antibiotics used and resistance
to them is rather simplified given the relatively compli-
cated ecological relationship between a bacterium and
an antibiotic. Neither the defined daily doses nor the
absolute annual consumption of antibiotics take into
account important factors contributing to the develop-
ment and spread of resistance, such as treatment
adequacy, combination of antibiotics, proper dosage of
drugs, adherence to treatment duration and intervals
between individual doses. These factors possibly ex-
plain why the findings in several studies are very vari-
able. Other, more precise methods should be sought to
measure selection pressure and its influence on bacter-
ial resistance.
A hypothesis has been published that asserts an imagin-
ary threshold has been crossed and the resistance of
Enterobacteriaceae to broad-spectrum antibiotics is main-
tained through transfer of mobile genetic elements encod-
ing resistance [22]. That threshold is a certain level of
resistance genes circulating in the bacterial population that
are horizontally transmitted by recombination processes,
causing the unstoppable spread of antibiotic resistance in-
dependent on their consumption. This hypothesis could be
an explanation for the implication of our study that selec-
tion pressure does not play the main role in the increasing
resistance to fluoroquinolones in Enterobacteriaceae.
It is likely that in antibiotic groups where the reason-
able level of resistance has been exceeded, the increasing
trend will be impossible to reverse. This leads to a heret-
ical notion that rational antibiotic policy will neither re-
verse nor inhibit the increase of resistance and that this
may actually be the end of the antibiotic era. Nevertheless,
even this gloomy outlook should not discourage us from
adhering to or improving the principles of rational
antibiotic therapy as this is the only way of slowing this
negative trend. To maintain the susceptibility of bac-
teria to at least those antibiotics that are still effective
and to slow the increase of antibiotic resistance, it is
necessary to continuously adhere to the principles of
rational antibiotic policy and to try to define the deter-
minants of bacterial resistance more clearly in order to
introduce measures effectively preventing bacterial re-
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